December 2023 in “Journal of Investigative Dermatology” A specific type of immune cell plays a key role in causing alopecia areata and could be a target for treatment.
May 2023 in “The Journal of Immunology” Alopecia areata involves unique activation of certain immune cells.
CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.
77 citations
,
June 2002 in “Journal of Investigative Dermatology” CD44 variant changes start alopecia areata, but don't maintain it.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.
IL-18 signaling helps mature Tregs move into the thymus.
May 2024 in “International journal of medicine and psychology.” Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.
The CD4 protein may play a role in the behavior of certain skin cells, affecting their growth, movement, and differentiation.
July 2024 in “Journal of Investigative Dermatology” A new test helps find drugs to treat head and neck cancer by targeting c-Rel.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
30 citations
,
April 2007 in “Journal of Leukocyte Biology” Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.
May 2023 in “The Journal of Immunology” Expanding CD4+ Tregs can stop hair loss in alopecia areata.
2 citations
,
May 2024 in “International Journal of Molecular Sciences” Targeting CD169+ skin macrophages may help treat psoriasis.
1 citations
,
December 2022 in “Frontiers in Immunology” Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.
February 2011 in “Journal of Investigative Dermatology” New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.
140 citations
,
March 2013 in “The journal of immunology/The Journal of immunology” Memory regulatory T cells need IL-7, not IL-2, to stay in peripheral tissues.
6 citations
,
April 2017 in “Experimental dermatology” CD80CD86 deficiency causes hair loss by disrupting regulatory T cells.
July 2025 in “Journal of Investigative Dermatology” Enhancing Tregs can protect against alopecia areata.
November 2025 in “Journal of Investigative Dermatology” Certain immune cells in atopic dermatitis skin could be targeted for treatment.
46 citations
,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
147 citations
,
October 2021 in “Cancer Communications” RC48 shows promise for treating certain advanced cancers, but more research is needed.
48 citations
,
January 2024 in “Immune Network” IL-15 is key for T cell function and could help improve treatments for immune-related diseases.
69 citations
,
February 2008 in “The American journal of pathology” Controlled delivery of specific RNA and IL-4 restored hair growth in mice with autoimmune alopecia.
23 citations
,
January 2016 in “Frontiers in immunology” Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.
44 citations
,
November 2022 in “Frontiers in Immunology” TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
5 citations
,
November 2005 in “Journal of Investigative Dermatology” July 2017 in “Cancer Research” Krt15+ cells in mice can resist radiation, regenerate tissue, and start tumors, suggesting new cancer treatment targets.
October 2014 in “Cancer research” Blocking mTORC1 reduces skin tumor growth in mice.
38 citations
,
January 2016 in “Cell Death and Disease” The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.